preclinical white papers and articles
-
Software Opportunities And Challenges In The Life Sciences Industry
8/23/2022
Robust, low-maintenance integrations between ERP and specialty software can ensure a free flow of data to enable all-round visibility of activities and events in a life sciences company.
-
Two Technologies That Help Life Sciences Companies Scale For Massive Growth
8/22/2022
Learn the six reasons that make Coupa and NetSuite a great team for ushering massive growth for life sciences companies.
-
Relying On Nonclinical Development Basics For Your Program
8/8/2022
Enhance the ability to assemble the right experts to implement the best strategy when determining which nonclinical studies are necessary for a program.
-
Building Quality Into Everything We Do – From A To Z
7/7/2022
By having better control over our manufacturing processes we are able to minimize the risk of out-of-specification intermediates all the way through to final products.
-
Innovation Standardized – Bioseparation Methods For Biotherapeutics
7/5/2022
Discover the most impactful standards in liquid chromatography (LC) for biotherapeutics. The standardizations include methods, columns, standards, and robustness.
-
What Do I Do About Incidental Findings In Research?
5/23/2022
Find out how incidental findings can result from a standard, approved clinical test or intervention and can also be found from a research test or intervention.
-
The Clinical Development Plan: Ensuring Success
2/17/2022
For an early-stage pharma/biotech company, the Clinical Development Plan (CDP) can be extremely valuable and a key indicator of potential success of a program. This white paper highlights key components for developing and executing a clinical research strategy once the plan is in place.
-
How Preclinical And Nonclinical Studies Differ, And Where They Belong
1/11/2022
Learn when should each term be used, and the appropriate timelines for preclinical and nonclinical studies within a drug development program.
-
Analysis: Pharma’s Path Ahead For COVID-19 R&D
12/17/2021
Three pressing issues stand out and require the collaborative efforts of the biopharma industry to slow the pandemic, reduce deaths and hospitalizations, and return life to something resembles normality: understanding long COVID, growing the arsenal of anti-infectives and tackling virus variants.
-
An Evolving Biologics Landscape And Driving Innovation And Opportunity
12/7/2021
The biologics segment is expanding quickly, with respect to both the level of investment and number of new startups. Explore a more collaborative investment model, the development of novel devices and delivery technologies, and a natural evolution in the CDMO space.